Novo compounds Tresiba troubles

Share this article:

Novo Nordisk says it needed time to digest the FDA's February Tresiba rejection before making the news public, but Danish authorities disagree and are investigating the drugmaker over its decision to wait two days to make the FDA's decision public, reports Reuters.

The timeline as well as the news are critical aspects to the story, as Reuters notes that although the FDA delivered its decision after Danish financial markets closed, US markets were not, and trades were still possible. The Big Think included an hour-long conference call, reports Reuters, which says the company published the information at night on Sunday, February 10.

The FDA rejection was an investor upset, and the regulator said it needed cardiovascular safety information before it would consider the drug for approval. This fail gave Sanofi's Lantus franchise one less competitor, and delayed Novo's Tresiba entry by a few years.

Sydbank analyst Soren Lontoft Hansen told Reuters that this is more of a reputation problem for Novo, instead of a financial one, but that the financial aspect could become more significant were US shareholders to pursue a joint action lawsuit.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.